Angiotensin II receptor blockade and type 2 diabetic nephropathy
- 1 March 2002
- journal article
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 2 (2) , 101-105
- https://doi.org/10.1177/14746514020020020701
Abstract
ACE inhibitors have been shown to reduce albuminuria and slow the progression of nephropathy in type 1 diabetes. There are fewer data in type 2 patients.This publication has 15 references indexed in Scilit:
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors?Annals of Internal Medicine, 2001
- Angiotensin II and its receptors in the diabetic kidneyAmerican Journal of Kidney Diseases, 2000
- Nephropathy in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Pathogenesis, prevention, and treatment of diabetic nephropathyThe Lancet, 1998
- Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect?Nephrology Dialysis Transplantation, 1997
- Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor TherapyAnnals of Internal Medicine, 1992